Rozległa delecja w genie KAL1 u dwóch spokrewnionych pacjentów z hipogonadyzmem hipogonadotropowym: użyteczność diagnostyczna technik cytogenetycznych i molekularnych by Krzymińska, Anna et al.
224
Prace oryginalne/original PaPers
Endokrynologia Polska/Polish Journal of Endocrinology
Tom/Volume 62; Numer/Number 3/2011
ISSN 0423–104X
Large deletion in the KAL1 gene in two related patients  
with hypogonadotropic hypogonadism:  
diagnostic usefulness of cytogenetic and molecular methods
Rozległa delecja w genie KAL1 u dwóch spokrewnionych pacjentów  
z hipogonadyzmem hipogonadotropowym: użyteczność diagnostyczna technik 
cytogenetycznych  i molekularnych
Anna Krzymińska1, Maciej Hilczer2, 3, Wanda Hawuła4, Anna Ulańska4, Lucjusz Jakubowski1, 4
1Department of General and Experimental Pathology, Medical University of Lodz, Poland  
2Department of Paediatric Endocrinology, Medical University of Lodz, Poland 
3Department of Endocrinology and Metabolic Diseases, Polish Mothers’ Memorial Hospital, Research Institute in Lodz, Poland 
4Department of Genetics, Polish Mothers’ Memorial Hospital, Research Institute in Lodz, Poland
Abstract
Background: Kallmann syndrome type 1 (KS1) is a heterogeneous disorder where hypogonadotropic hypogonadism (HH) associated with 
an impaired sense of smell is observed. The aim of this study was to investigate the usefulness of the multiplex ligation-dependent probe 
amplification (MLPA) technique for differential diagnosis in comparison with molecular cytogenetics — fluorescence in situ hybridisation 
(FISH) or traditional PCR analysis and propose a diagnostic approach for patients with KS. 
Material and methods: Karyotype and PCR analysis in two related patients and other family members were performed, followed by 
MLPA dosage sensitive analysis. 
Results: In the proband and his maternal uncle, the PCR allowed the detection of a large deletion within the KAL1 gene, from exon 4 to 
14 (c.469-?_6314+?del). The deletion was also diagnosed in three female carriers in the presented family. These results were proved by 
the MLPA technique. Moreover, we traced the presence of the region located downstream and upstream to the KAL1 gene on Xq22.32. 
However, FISH analysis failed to reveal any deletion in the critical region for KS. Simultaneously, we report difficulties connected with 
the PCR technique based on the primers for KAL1 amplification presented in the literature. We designed primers that are specific to the 
X chromosome and bypass pseudogene KALY amplification. 
Conclusions: FISH analysis is a convenient screening technique, but in the presented family it failed to detect the deletion. Therefore, 
in the face of a distinctive manifestation of KS, a subsequent molecular assay should be introduced. The MLPA is a useful technique for 
differential diagnosis in patients with HH combined with smell impairment. (Pol J Endocrinol 2011; 62 (3): 224–229)
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Streszczenie
Wstęp: Zespół Kallmanna typu 1 (ZK1) jest zaburzeniem heterogennym, w którym cechy hipogonadyzmu hipogonadotropowego mogą 
współistnieć z upośledzeniem węchu. Choroba ta może występować sporadycznie lub rodzinnie. Celem pracy była ocena użyteczności 
metody amplifikacji multipleks zależnej od ligacji sond (MLPA) w porównaniu z technikami cytogenetyki molekularnej i PCR w diag-
nostyce różnicowej ZK oraz zaproponowanie schematu postępowania diagnostycznego w jego przypadkach. Wczesne rozpoznanie ZK 
umożliwia leczenie objawowe z korzystnym efektem dla rozwoju cech płciowych i płodności u części chorych.
Materiał i metody: Badania przeprowadzono u 2 spokrewnionych chorych i członków ich rodziny. Oceniano kariotyp za pomocą technik 
cytogenetyki klasycznej i molekularnej — fluoroscencyjnej hybrydyzacji in situ (FISH). W badaniach DNA wykorzystano PCR, a następnie 
MLPA pod kątem jego analizy jakościowej i ilościowej. 
Wyniki: U probanta i jego wuja za pomocą PCR wykryto delecję obejmującą eksony od 4 do 14 (c.469-?_6314+?del) genu KAL1. U trzech 
kobiet z rodziny pacjentów stwierdzono nosicielstwo tej delecji. Nie uwidoczniono jej za pomocą FISH z sondą specyficzną dla regionu 
krytycznego obejmującego KAL1. Obecność delecji potwierdzono, stosując MLPA. Udokumentowano jednocześnie obecność sekwencji 
położonych poniżej i powyżej genu KAL1 na wysokości prążka Xq22.32. W pracy zilustrowano również trudności związane z amplifika-
cją KAL1 przy zastosowaniu starterów opisanych w literaturze. Zaprojektowano własne sekwencje starterów, wykluczające jednoczesną 
amplifikację pseudogenu KALY.
Wnioski: Metoda FISH jest dogodną techniką przesiewową w diagnostyce mikrodelecji, jednak w przypadku prezentowanej w pracy 
rodzinie nie pozwoliła na wykrycie delecji wewnątrzgenowej. U chorych z objawami odpowiadającymi ZK należy zatem w podobnych 
przypadkach zastosować inne metody analizy molekularnej. Potwierdzono użyteczność techniki MLPA w diagnostyce różnicowej pa-
cjentów z HH i zaburzeniami węchu. (Endokrynol Pol 2011; 62 (3): 224–229)
Słowa kluczowe: hipogonadyzm hipogonadotropowy (HH), zespół Kallmanna (ZK), mutacja genu KAL1, FISH, MLPA
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Introduction
Kallmann syndrome is a clinically and genetically het-
erogenous disease that presents a diverse phenotype 
spectrum. However, hypogonadotropic hypogonadism 
(HH) associated with an impaired sense of smell, either 
partial (hyposmia) or total (anosmia) is the most frequent 
feature. The prevalence of the disease has been estimated 
at 1/8,000 in males and 1/40,000 in females, although it 
might have been underestimated, especially in women 
[1]. The physiological base for HH is specified and lo-
calised in detail, unlike the molecular bases which are 
still under investigation. The clinical phenotype of HH 
includes a wide range of symptoms ranging from absolute 
default of sexual maturation with subsequent infertility, 
to partial puberty and an almost normal testicular size 
with a eunuchoidal body habitus. Hypogonadotropic 
hypogonadism (secondary hypogonadism) is the result 
of an isolated deficiency of gonadotropin-releasing 
hormone from the hypothalamus with pubertal delay 
and subsequent infertility. Some of the symptoms can 
be diminished by hormone replacement therapy with 
a subsequent improvement in the patient’s physical and 
psychological condition. Early diagnosis can lead to en-
dogenous sex-steroid secretion and even reproduction [2].
The following three modes of Kallmann syndrome 
inheritance have been described: X-chromosome 
linked, autosomal dominant, and autosomal recessive; 
nevertheless sporadic cases are most frequent [1–5]. Six 
causative genes responsible for KS manifestation have 
been found to date: KS 1 (mutations within KAL1), KS 
2 (FGFR1), KS 3 (PROKR2), KS 4 (PROK2), KS 5 (CHD7), 
and KS 6 (FGF8). These are presented with their chromo-
somal position and a short clinical description in Table I. 
However, it is believed that mutations in these genes 
account for only 30% of all KS cases [3]. The explanation 
behind the connection of hypogonadotropic hypogonad-
ism and anosmia in KS 1 is the common origin of GnRH 
neurons and mitral cells (which produce the KAL1 gene 
product — anosmin-1) from the olfactory placode. Anos-
min-1 plays an essential role during foetal development 
in neuronal migration from the olfactory tract through 
the cribriform plate and the forebrain until it reaches the 
hypothalamus [6–9]. A mutation in the KAL1 gene, there-
fore, manifests itself as hypogonadotropic hypogonadism 
combined with lack of smell (anosmia).
Among the causes of X chromosome-linked Kall-
mann syndrome, translocations and deletions within 
the fragile critical Xp22 region have been described. 
KAL1 gene mutations include missense and nonsense 
mutation, splice site mutations, point (a single base) 
deletions, intragenic insertions and deletions, as well 
as submicroscopic chromosomal deletions involving 
the entire KAL1 gene [10]. Here, we report the case of 
a deletion of exons 4 to 14 (c.469-?_6314+?del) within the 
KAL1 gene in two related patients and in three female 
carriers among the members of the presented family.
Materials and methods 
The study group
The patients and their four relatives included in the study 
gave their written consent for participation in the genetic 
analysis (the medical research being scheduled in accord-
Table I. Types of Kallmann syndrome (KS). Elaboration based on ‘Online Mendelian Inheritance in Man’ (OMIM) from 
database of National Centre for Biotechnology Information (www.ncbi.nlm.nih.gov/omim)
Tabela I. Typy zespołu Kallmanna (ZK). Opracowano na podstawie bazy „Online Mendelian Inheritance in Man” (OMIM) 
dostępnej na stronie National Center for Biotechnology Information (www.ncbi.nlm.nih.gov/omim)
Kallmann syndrome 
type
OMIM Gene map locus Gene Most distinctive features  
apart from hypogonadotropic hypogonadism
Kallmann syndrome 
type 1
308700 Xp22.32 KAL1 Anosmia/hyposmia, bimanual synkinesia (mirror movements), 
renal agenesis, pes cavus, high-arched palate, and cerebellar 
ataxia. Rarely, colour blindness
Kallmann syndrome 
type 2
147950 8p11.2-p11.1 FGFR1 Anosmia/hyposmia. Midline cranial anomalies (cleft lip, cleft 
palate and imperfect fusion)
Kallmann syndrome 
type 3
244200 20p13 PROKR2 Wide spectrum of olfactory and reproductive dysfunction 
without any distinctive manifestations
Kallmann syndrome 
type 4
610628 3p21.1 PROK2 Wide spectrum of olfactory and reproductive dysfunction 
without any distinctive manifestations
Kallmann syndrome 
type 5
612370 8q12.1 CHD7 Cleft lip and palate. Hearing disorders. Clinical manifestations 
reflecting CHARGE syndrome
Kallmann syndrome 
type 6
612702 10q24 FGF8 Varied degrees of gonadotropin-releasing hormone deficiency 
and olfactory function disability
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ance with the World Medical Association Declaration of 
Helsinki). The family pedigree is presented in Figure 1.
The proband LG471 (position III–7; Figure 1) is the 
second child born to healthy, non-consanguineous 
parents. He was admitted to the Department of Endocri-
nology and Metabolic Diseases, as well as to the genetic 
counselling centre, on account of delayed puberty and 
hypogonadism symptoms. His height was 181 cm and 
his weight was 87 kg. A eunuchoid profile, slight gyneco-
mastia, small penis and scrotal testes with the dimensions: 
right — 19 × 12 × 11 mm and left – 20 × 12 × 12 mm and 
slightly enlargement nipples were noted. On examina-
tion, involuntary upper limb mirror movements were 
observed. The patient declared an impairment of smell, 
but no olfactory tests were formally performed. Serum 
levels of hormones were as following: LH — 0.217 U/l 
[normal range: 1.7–8.6 IU/l], FSH — 0.718 IU/l [normal 
range: 1–14 IU/l], estradiol — 16.88 pg/ml [normal range: 
7.63–42.6 pg/ml] and testosterone — 0.292 ng/ml [normal 
range 2.8–8.0 ng/ml]. Magnetic resonance imaging of the 
pituitary gland revealed normal homogeneous structure 
of the parenchyma with an intact hypothalamic infundibu-
lum. Cytogenetic analysis revealed a 46,XY karyotype. 
The proband’s maternal uncle ZL567 (II-1) was ad-
mitted to the Department of Genetics after his nephew 
was diagnosed with Kallmann syndrome type 1, which 
aroused suspicion of familial expression of the disease. 
Hormonal evaluation showed low testosterone level 
[0.322 ng/ml] and LH level [< 0.100 IU/l]. The patient 
was diagnosed with chronic arthritis of the femoral 
joint. He is unmarried and has no children. Cytogenetic 
analysis showed a normal 46,XY karyotype.
The other maternal uncle (II-8) of proband LD471 
objected to genetic counselling.  Historic data suggests 
he is also a carrier of the detected deletion. He is married 
but has no children, only an adopted one. 
Cytogenetic evaluation and fluorescence in situ 
hybridisation (FISH)
The karyotype of peripheral blood lymphocytes 
(leucocytes) was analysed, applying standard culture 
techniques and GTG-banding of the chromosomes. The 
FISH was carried out on lymphocyte metaphase spreads 
with LSI Kallmann’s (KAL Spectrum Orange/CEPX) 
Region Probe (Vysis, Abbott Molecular, USA) and DXZ1 
(spectrum Green) probe for the X-centromere as internal 
signal control following the manufacturer’s protocol. 
Genomic DNA extraction
Genomic DNA was isolated from 5 ml of the whole 
peripheral blood by means of the QIAamp DNA blood 
mini kit (Qiagen, USA), according to the enclosed pro-
tocol. Additionally, genomic DNA from a healthy male 
was isolated as a control.
PCR amplification
PCR amplification (reaction profile and primers se-
quences) conditions were as published by Hardelin et 
Figure 1. The pedigree of the described family. The proband LG471 is indicated with an arrow (position III-7). LG471 and ZL567 (II-1) 
are the carriers of the detected KAL1 gene deletion (black square). Hemizygous female carriers (half-hatched circle) are: the proband’s 
mother II-7, and sisters: III-6 and III-8. Proband’s grandmother (I-2) deceased, but from the pedigree analysis we may infer that she was 
also the deletion carrier. II-8 — suspicion of KS (more details in text)
Rycina 1. Rodowód badanej rodziny. Probant LG471 wskazany jest strzałką (pozycja III-7). Pacjenci (czarne kwadraty) LG471 oraz 
ZL567 (II-1) są nosicielami wykrytej delecji w genie KAL1. Hemizygotycznymi nosicielkami żeńskimi (oznaczonymi zakreskowanym do 
połowy kołem) są: matka probanta (II-7) oraz siostry: II-6 i III-8. Babka probanta (I-2) zmarła, jednakże na podstawie analizy rodowodu 
można wnioskować, że również była nosicielką wykrytej delecji. II-8 — podejrzenie ZK (więcej szczegółów w tekście)
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al. with modification [11] but the primers for exons 1, 
11, 12 and 14 were designed individually. 
These are: exon 1, F:AGGTCGGCGAGGAGGGTC 
and  R :GGAAGAGGCTGGAAAGGAGAGTT; 
exon  11 ,  F:GCATATCCCGCAGCCATG and 
R :TCCTACATCTCTTCCCTCCACAT;  e xo n 
1 2 ,  F :ATCCCTTGGGCACACCTTCTC  and 
R:ACTCAATAGTGCAGCACACAGAAT; exon 14, 
F:AAAGGAGAGAAAGAGTGTGGTTGTA and 
R:GCTTGTAGGGAACTGGTGTCTG. 
PCR reactions were carried out in a total reaction 
mixture volume of 25 μl, containing 1 μg of genomic 
DNA [concentration 10–50 ng/μl], 1 unit FastStart Taq 
DNA Polymerase, 1.5 mM MgCl2, 0.2 mM dNTPs and 100 
pM of the primers. PCR amplifications were performed 
for 32 cycles on a BioRad C1000 Thermal Cycler. The 
PCR products were visualised on 2% agarose gel with 
ethidium bromide addition and registered by means of 
the Photodocumentation System DP.-001.FDC (Vilber 
Lourmat, France). 
Multiplex Ligation-dependent Probe  
Amplification analysis (MLPA)
Gene dosage analysis was performed using the SALSA® 
MLPA kit Kallmann-1 P132 (MRC-Holland, the Nether-
lands). The kit includes 16 probes that attach to KAL1 gene 
sequence on chromosome Xp22.32 (one probe per exons 
2 to 13, two probes per exons 1 and 14) and 17 control 
probes that hybridise to sequences located upstream and 
downstream, according to KAL1 locus. The assay was 
performed according to the manufacturer’s manual. After 
the PCR, amplicons were run on an ABI 3130xl Genetic 
Analyser (Applied Biosystems, USA) using ROX 500 size 
standard. Analysis of obtained peaks (measurement of 
each peak area) was performed by GeneMarker software 
V 1.90 (SoftGenetics LLC, USA) and normalised by divid-
ing an individual peak by the combined area of all peaks 
in the lane. The patients’ dosage histograms and ratio 
plot were compared to those obtained from healthy indi-
viduals by visual examination. Simultaneously, any visual 
disagreements were confirmed by information displayed 
in the report table (where peak ratio or simple loss/gain 
information was presented). Any minimum dosage quo-
tient beyond the range < 0.75 or > 1.30 was considered 
abnormal and corresponded to deletion and duplication, 
respectively. Whenever we found a sample with an ab-
normal dosage quotient, the sample was re-analysed by 
the MLPA. Only the samples showing consistent results 
between the two tests were taken into consideration.
Results
To the assay, we subjected the proband LG471 (III-7) 
and his relatives: mother (II-7), father (II-6), two sis-
ters (III-6; III-8) and uncle ZL567 (II-1). The molecular 
analysis of the proband LG471 and maternal uncle 
ZL567 by means of the PCR showed a large deletion 
within KAL1 (Figure 2) that encompasses exons from 4 
to 14 (c.469-?_6314+?del) and does not extend beyond 
KAL1 since we detected signals for STS and HDHD1 
genes (both are on Xp22.32) located downstream to the 
KAL1 gene. However, the FISH analysis with the use of 
a specific probe, LSI KAL1 that hybridises to the KAL1 
gene, failed to confirm this deletion (data not shown). 
Figure 2. Examples of electrophoregrams of amplification products obtained from PCR with the use of primers that are complementary 
to the exons 3 and 4 of the KAL1 gene. M: size marker; 1: positive control (healthy male); 2–15: patients’ samples; 4: proband (LG471; 
III-7); 5: proband’s sister (III-6); 6: proband’s sister (III-8); 7: proband’s mother (II-7); 8: proband’s father (II-6); 9: proband’s uncle 
(ZL567; II-1); 16: negative control (PCR reagents without DNA template). Absence of the amplification products in lanes 4 (proband) 
and 9 (proband’s uncle) for exon 4 is observed. The same results for exons 5–14 were obtained in both patients
Rycina 2. Przykładowe elektroforegramy produktów PCR uzyskanych przy użyciu starterów komplementarnych do sekwencji 3. i 4. 
eksonu genu KAL1. M: marker wielkości; 1: kontrola pozytywna (zdrowy mężczyzna); 2–15: próbki pacjentów; 4: probant (LG471; III-7); 
5: siostra probanta (III-6); 6: siostra probanta (III-8); 7: matka probanta (II-7); 8: ojciec probanta (II-6); 9: wuj probanta (ZL567; II-1); 
16: kontrola negatywna (odczynniki PCR bez DNA matrycowego). Takie same wyniki u obu pacjentów otrzymano dla eksonów 5–14
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In further analysis, the MLPA technique with the use 
of the Kallmann 1 P132 kit confirmed the obtained PCR 
results. Moreover, thanks to a dosage-sensitive MLPA 
application, we detected carrier status in the proband’s 
mother (II-7) as well as in his two sisters (III-6 and III-8) 
who possessed a hemizygous KAL1 gene and did not 
manifest any signs of Kallmann syndrome (Figure 3).
In this paper, we substantiate a family’s KAL1 gene 
transmission with the same deletion which does not 
affect female fecundity within this family (on mother 
II-7, and sisters: III-6 and III-8). We observed that FISH 
analysis for the critical region in the absence of ad-
ditional clinical manifestations for contiguous gene 
syndrome (CGD) is not an effective technique. It is es-
sential to perform a complete diagnostic procedure in 
order to detect this rearrangement. 
Discussion 
Since the genetic ground of KS is very heterogeneous, 
a differential clinical picture of the disease can be ob-
served. Phenotype-genotype correlation analyses of the 
disease show that the manifestation of KS is determined 
by alternative factors other than the mutation itself. 
These factors may encompass modifier genes, epigen-
etic and environmental factors. 
Many cases are clearly familial with X-chromosome 
linked, autosomal dominant and autosomal recessive 
inheritance, but most cases are sporadic. The molecular 
analysis of KS to date has included mutations of the: 
KAL1, FGRF1, PROKR2, PROK2, CHD7 and FGF8 genes, 
which accounts for 30% of all KS cases, suggesting that 
there might be more genes involved in the development 
of the disease, or that the disease escapes the monogenic 
Mendelian heritable pattern. 
Moreover, it seems that mutations in some genes 
show incomplete penetrance [2, 11–13]. In their extensive 
report concerning the complex genetics of IHH (idiopathic 
hypogonadotropic hypogonadism), Pitteloud et al. [12] 
argued that oligogenicity might be responsible for mo-
nogenic IHH disorders presenting variable phenotypes 
within and between families. The majority of PROK2 and 
Figure 3. Electrophoregram illustrating deletion of KAL1 detected by means of the MLPA. Multi-exon deletion extending from exon 4 to 
14 (c.469-?_6314+?del) is indicated in the light grey boxes connected with black arrows showing absence (in the proband LG471; III-7) or 
lower peaks (in the proband’s mother II-7) of KAL1 probes (dark grey) compared to the control peaks (light red). On the right in the Report 
Table, loss information is displayed together with the probe number and  the basepair size of that probe (ranging from 91 to 398 bp).  Probe 
size corresponds as follows: 147 — exon 14; 165 — exon 7; 184 — exon 8; 230 — exon 9; 241 — exon 10; 255 —  exon 4; 265 — exon 
11; 283 — exon 6; 293 — exon 12; 310 — exon 5; 318 — exon 11; 347 — exon 14. Note: probe size 241 (indicated in the ellipse) is not 
reliable according to the manufacturer’s notes, since a signal via this probe might be also obtained on a chromosome Y sequence
Rycina 3. Elektroferogram przedstawiający delecję w KAL1 wykrytą za pomocą techniki MLPA. Wieloeksonową delecję obejmującą eksony 
od 4. od 14. (c.469-?_6314+?del) zaznaczono jasnoszarymi prostokątami ze strzałkami wskazującymi brak ciemnoszarych pików (probant 
LG471; III-7) lub obniżone piki (u matki probanta; II-7) dla sond genu KAL1, w odniesieniu do referencyjnych — jasnoszarych pików. 
Po prawej stronie ryciny w „Report table” przedstawiono wartość ubytku materiału genetycznego w próbie wraz z przyporządkowanym 
numerem sondy (który jednocześnie informuje o wielkości produktu). Wielkości sond odpowiadają następującym eksonom: 
147 — ekson 14.; 165 — ekson 7.; 184 ekson — 8.; 230 — ekson 9.; 241 — ekson 10.; 255 — ekson 4.; 265 — ekson 11.; 283 — ekson 6.; 
293 — ekson 12.; 310 — ekson 5.; 318 — ekson 11.; 347 — ekson 14. Sygnał dla sondy 241 (zaznaczonej elipsą) zgodnie z informacją 
podaną przez producenta zestawu nie jest wiarygodny, gdyż umożliwia również amplifikację odcinka pseudogenu chromosomu Y
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PROKR2 mutations are monoallelic, but there are some 
cases where mutations on both alleles of either gene are 
detected [13]. Additionally, male patients with detected 
biallelic mutations in PROK2 or PROKR2 suffer from more 
severe disorders of the reproductive system [13]. Hardelin 
and Dode [3] recognized KS as the result of insufficient 
cell signalling through FGFR or PROKR2, therefore the 
mutation within FGFR1 and PROK2 disrupts the nor-
mal embryonic development (FGF signalling, fibroblast 
growth factor signalling) and the integration of intracel-
lular signalling (prokinecitin signalling). Anosmin-1 (the 
product of KAL1) acts as an enhancer of FGF and, prob-
ably, of prokinecitin signalling as well. 
Kallmann syndrome type 1 rarely arises from a dele-
tion which encompasses only the KAL1 gene (Xp22.32). 
The majority of mutations in KS 1 are point mutations 
and small deletions or duplications (1–2 exons). Large 
deletions are rare, and only a very few gross deletions 
have been reported due to the difficulty in detecting 
them using a PCR-based DNA sequencing [14]. 
We have managed to detect a large deletion that does 
not exceed the KAL1 gene sequence and includes exons 
from 4 to 14 (c.469-?_6314+?del). Despite the magnitude 
of this deletion, FISH studies with DNA probes specific 
to the KAL1 gene sequence did not detect it. Probably 
the rearrangement in the critical region must be much 
larger, and exceed the KAL1 gene, to be detected by the 
FISH technique. Mutated KAL1 gene participation in 
males in contiguous gene syndrome (CGS), including 
the loss of genes responsible for Leri-Weill syndrome 
and some cases of short stature, chondrodysplasia 
punctata, Duchenne dystrophy, ichthyosis, mental 
retardation or ocular albinism, is more common [2, 5]. 
Clinical features of KS in CGS apply on a more com-
plex phenotype which is a combination of distinctive 
features for each disease entity. A diagnosis based solely 
on the PCR technique and sequencing data might be 
misleading, since the KAL1 gene has its pseudogene 
KALY located on chromosome Y. Some amplicons ob-
tained via the PCR may originate from KALY amplifica-
tion, and sequencing analysis in males can be difficult 
to interpret [15, 16].
Conclusions
Screening for KS in patients with HH, especially if the 
condition is accompanied by anosmia/hyposmia, is 
crucial in making an accurate diagnosis. Concurrently, 
an early diagnosis of KS, symptomatic treatment and 
regular follow-up are beneficial for patients in order to 
prevent them from pernicious sequelae and improve 
their sexual development. Several molecular techniques 
should be applied to diagnose the rearrangements in 
the KS critical region. FISH failed to detect in this family 
the large intragenic deletion. MLPA seems to be a useful, 
rapid technique for differential diagnosis in patients 
with HH combined with smell impairment.  
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